Advertisement

Psychopharmacology

, Volume 231, Issue 11, pp 2251–2259 | Cite as

The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study

  • Michael A. P. Bloomfield
  • Celia J. A. Morgan
  • Shitij Kapur
  • H. Valerie Curran
  • Oliver D. HowesEmail author
Original Investigation

Abstract

Rationale

Cannabis is the most widely used illicit drug in the world, and regular use has been associated with reduced motivation, i.e. apathy. Regular long-term cannabis use has been associated with reduced dopamine synthesis capacity. The mesolimbic dopaminergic system mediates the processing of incentive stimuli by modifying their motivational value, which in turn is modulated by endocannabinoid signalling. Thus, it has been proposed that dopaminergic dysfunction underlies the apathy associated with chronic cannabis use.

Objectives

The aim of this study was to examine the relationship between dopaminergic function and subjective apathy in cannabis users.

Methods

We measured dopamine synthesis capacity (indexed as the influx rate constant K i cer ) via 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine positron emission tomography and subjective apathy using the self-rated Apathy Evaluation Scale (AES-S) in 14 regular cannabis users.

Results

All subjects scored in excess of 34 points on the AES-S (median [interquartile range] 59.5 [7.5]), indicative of significant apathy based on normative data. K i cer was inversely correlated to AES-S score in the whole striatum and its associative functional subdivision (Spearman’s rho = −0.64, p = 0.015 [whole striatum]; rho = −0.69, p = 0.006 [associative]) but not in the limbic or sensorimotor striatal subdivisions. There were no significant relationships between AES-S and current cannabis consumption (rho = 0.28, p = 0.34) or age of first cannabis use (rho = 0.25, p = 0.40).

Conclusions

These findings indicate that the reduction in striatal dopamine synthesis capacity associated with chronic cannabis use may underlie reduced reward sensitivity and amotivation associated with chronic cannabis use.

Keywords

Apathy Cannabis Drugs Dopamine Imaging Motivation PET 

Notes

Acknowledgments

Our study was funded by a Medical Research Council (UK) grant to Dr. Howes (grant number: MC-A656-5QD30), a National Institute of Health Research Biomedical Research Council grant to King’s College London and a Medical Research Council (UK) grant to Professor Curran and Dr Morgan. We thank our subjects, the radiographers and staff of GE Imanet for their assistance with PET scans and Professor Federico Turkheimer for statistical and methodological advice.

Conflict of interest

The authors declare no financial conflict of interest. The authors have full control of all primary data, and they agree to allow the journal to review their data if requested.

References

  1. Akinci IH, Tarter RE, Kirisci L (2001) Concordance between verbal report and urine screen of recent marijuana use in adolescents. Addict Behav 26:613–619PubMedCrossRefGoogle Scholar
  2. Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM, Mock BH, Zheng QH, Federici LA, Patton EA, Herring CM, Yoder KK (2013) Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend 128:52–57PubMedCentralPubMedCrossRefGoogle Scholar
  3. American Psychiatric Association (2005) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision edn. American Psychiatric Association, Washington, DCGoogle Scholar
  4. Anthony JC, Warner LA, Kessler RC (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 2:244–268CrossRefGoogle Scholar
  5. Barbas H (2000) Connections underlying the synthesis of cognition, memory, and emotion in primate prefrontal cortices. Brain Res Bull 52:319–330PubMedCrossRefGoogle Scholar
  6. Barkus EJ, Stirling J, Hopkins RS, Lewis S (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39:175–178PubMedCrossRefGoogle Scholar
  7. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S, Murray RM (2011) Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 25:1462–1468PubMedCrossRefGoogle Scholar
  8. Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain research. Brain Res Rev 28:309–369PubMedCrossRefGoogle Scholar
  9. Biggio G, Porceddu ML, Gessa GL (1976) Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-3′,5′-monophosphate content in the rat caudate nucleus induced by the acute administration of an aminoacid mixture lacking tyrosine and phenylalanine. J Neurochem 26:1253–1255PubMedCrossRefGoogle Scholar
  10. Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD (2013) Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry. doi: 10.1016/j.biopsych.2013.05.027 Google Scholar
  11. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE (2000) Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 32(Suppl: i-iv):1–112CrossRefGoogle Scholar
  12. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 34:759–766CrossRefGoogle Scholar
  13. Breivogel CS, Childers SR (2000) Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328–336PubMedGoogle Scholar
  14. Brook JS, Adams RE, Balka EB, Johnson E (2002) Early adolescent marijuana use: risks for the transition to young adulthood. Psychol Med 32:79–91PubMedCrossRefGoogle Scholar
  15. Brown CA, Campbell MC, Karimi M, Tabbal SD, Loftin SK, Tian LL, Moerlein SM, Perlmutter JS (2012) Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys. Exp Neurol 236:190–197PubMedCentralPubMedCrossRefGoogle Scholar
  16. Buchan BJ, L Dennis M, Tims FM, Diamond GS (2002) Cannabis use: consistency and validity of self-report, on-site urine testing and laboratory testing. Addiction 97:98–108PubMedCrossRefGoogle Scholar
  17. Cherek DR, Lane SD, Dougherty DM (2002) Possible amotivational effects following marijuana smoking under laboratory conditions. Exp Clin Psychopharmacol 10:26–38PubMedCrossRefGoogle Scholar
  18. Cumming P, Leger GC, Kuwabara H, Gjedde A (1993) Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]FDOPA) in humans. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 13:668–675CrossRefGoogle Scholar
  19. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B (2002) Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 40:2257–2267PubMedCrossRefGoogle Scholar
  20. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD (2010) The test–retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. NeuroImage 50:524–531PubMedCrossRefGoogle Scholar
  21. European Monitoring Centre for Drugs and Drug Addiction (2013) European drug report 2013: trends and developments. European Monitoring Centre for Drugs and Drug Addiction, LisbonGoogle Scholar
  22. Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA (1992) Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42:838–845PubMedGoogle Scholar
  23. Fergusson DM, Horwood LJ, Beautrais AL (2003) Cannabis and educational achievement. Addiction 98:1681–1692PubMedCrossRefGoogle Scholar
  24. Fernandez-Artamendi S, Fernandez-Hermida JR, Garcia-Fernandez G, Secades-Villa R, Garcia-Rodriguez O (2013) Motivation for change and barriers to treatment among young cannabis users. Eur Addict Res 19:29–41PubMedCrossRefGoogle Scholar
  25. Fernandez-Ruiz J, Hernandez M, Ramos JA (2010) Cannabinoid–dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e72–e91PubMedCrossRefGoogle Scholar
  26. First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric, Washington, DCGoogle Scholar
  27. Foltin RW, Fischman MW, Brady JV, Kelly TH, Bernstein DJ, Nellis MJ (1989) Motivational effects of smoked marijuana: behavioral contingencies and high-probability recreational activities. Pharmacol Biochem Behav 34:871–877PubMedCrossRefGoogle Scholar
  28. French ED (1997) Delta9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226:159–162PubMedCrossRefGoogle Scholar
  29. Garavan H, Pankiewicz J, Bloom A, Cho JK, Sperry L, Ross TJ, Salmeron BJ, Risinger R, Kelley D, Stein EA (2000) Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 157:1789–1798PubMedCrossRefGoogle Scholar
  30. Ginovart N, Tournier BB, Moulin-Sallanon M, Steimer T, Ibanez V, Millet P (2012) Chronic Delta(9)-tetrahydrocannabinol exposure induces a sensitization of dopamine D(2)/(3) receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 37:2355–2367CrossRefGoogle Scholar
  31. Govaerts SJ, Hermans E, Lambert DM (2004) Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur J Pharm Sci 23:233–243PubMedCrossRefGoogle Scholar
  32. Gruber AJ, Pope HG, Hudson JI, Yurgelun-Todd D (2003) Attributes of long term heavy cannabis users: a case–control study. Psychol Med 33:1415–1422PubMedCrossRefGoogle Scholar
  33. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279–287PubMedCrossRefGoogle Scholar
  34. Guttman M, Leger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A (1993) Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord Off J Mov Disord Soc 8:298–304CrossRefGoogle Scholar
  35. Harper AE, Benevenga NJ, Wohlhueter RM (1970) Effects of ingestion of disproportionate amounts of amino acids. Physiol Rev 50:428–558PubMedGoogle Scholar
  36. Harrison LD, Martin SS, Enev T, Harrington D (2007) Comparing drug testing and self-report of drug use among youths and young adults in the general population (DHHS Publication No. SMA 07-4249, Methodology Series M-7). Substance Abuse and Mental Health Services Administration, Office of Applied Studies, RockvilleGoogle Scholar
  37. Hartvig P, Aquilonius SM, Tedroff J, Reibring L, Agren H, Bjurling P, Ulin J, Langstrom B (1991) Positron emission tomography of L-dopa utilization in the brains of rhesus monkeys and human volunteers. Acta Radiol Suppl 376:149–150PubMedGoogle Scholar
  38. Hartvig P, Torstenson R, Tedroff J, Watanabe Y, Fasth KJ, Bjurling P, Langstrom B (1997) Amphetamine effects on dopamine release and synthesis rate studied in the rhesus monkey brain by positron emission tomography. J Neural Transm 104:329–339PubMedCrossRefGoogle Scholar
  39. Horwood LJ, Fergusson DM, Hayatbakhsh MR, Najman JM, Coffey C, Patton GC, Silins E, Hutchinson DM (2010) Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend 110:247–253PubMedCrossRefGoogle Scholar
  40. Hoshi H, Kuwabara H, Leger G, Cumming P, Guttman M, Gjedde A (1993) 6-[18F]Fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 13:57–69CrossRefGoogle Scholar
  41. Indian Hemp Drugs Commission (1893 [Reprinted 1969]) Marijuana: report of the Indian Hemp Drugs Commission. Thomas Jefferson, Silver SpringsGoogle Scholar
  42. Joel D, Weiner I (2000) The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96:451–474PubMedCrossRefGoogle Scholar
  43. Kamien JB, Bickel WK, Higgins ST, Hughes JR (1994) The effects of Delta(9)-tetrahydrocannabinol on repeated acquisition and performance of response sequences and on self-reports in humans. Behav Pharmacol 5:71–78PubMedGoogle Scholar
  44. Kandel DB, Davies M, Karus D, Yamaguchi K (1986) The consequences in young adulthood of adolescent drug involvement. An overview. Arch Gen Psychiatry 43:746–754PubMedCrossRefGoogle Scholar
  45. Kant R, Duffy JD, Pivovarnik A (1998) Prevalence of apathy following head injury. Brain Inj 12:87–92PubMedCrossRefGoogle Scholar
  46. Kelley BG, Thayer SA (2004) Delta 9-tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 46:709–715PubMedCrossRefGoogle Scholar
  47. Koob GF, Le Moal M (2005) Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nat Neurosci 8:1442–1444PubMedCrossRefGoogle Scholar
  48. Kuepper RC, Lataster J, van Os J, van Kroonenburgh M, van Gerven JMA, Marcelis M, VanLaere K, Henquet C (2013) Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS ONE 8(7):e70378Google Scholar
  49. Lane SD, Cherek DR (2002) Marijuana effects on sensitivity to reinforcement in humans. Neuropsychopharmacology 56:520–529CrossRefGoogle Scholar
  50. Lane SD, Cherek DR, Cherek DR, Pietras CJ, Tcheremissine OV (2004) Acute marijuana effects on response–reinforcer relations under multiple variable-interval schedules. Behav Pharmacol 15:305–309PubMedCrossRefGoogle Scholar
  51. Lane SD, Cherek DR, Pietras CJ, Steinberg JL (2005) Performance of heavy marijuana-smoking adolescents on a laboratory measure of motivation. Addict Behav 30:815–828PubMedCrossRefGoogle Scholar
  52. Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 248:266–270PubMedCrossRefGoogle Scholar
  53. Levy R, Dubois B (2006) Apathy and the functional anatomy of the prefrontal cortex–basal ganglia circuits. Cereb Cortex 16:916–928PubMedCrossRefGoogle Scholar
  54. Looby A, Earleywine M (2007) Negative consequences associated with dependence in daily cannabis users. Subst Abus Treat Prev Policy 2:3CrossRefGoogle Scholar
  55. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Smith GD (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 263:1579–1588CrossRefGoogle Scholar
  56. Marin RS (1991) Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 3:243–254PubMedGoogle Scholar
  57. Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 38:143–162PubMedCrossRefGoogle Scholar
  58. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 23:285–300CrossRefGoogle Scholar
  59. Mason OJ, Morgan CJ, Stefanovic A, Curran HV (2008) The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 103:138–142PubMedCrossRefGoogle Scholar
  60. Maykut MO (1985) Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 9:209–238PubMedCrossRefGoogle Scholar
  61. McGlothin WH, West LJ (1968) The cannabis problem: an overview. Am J Psychiatr 125:370–378Google Scholar
  62. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 61(2):134–142Google Scholar
  63. Melis M, Pistis M (2012) Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond B Biol Sci 367:3276–3285PubMedCentralPubMedCrossRefGoogle Scholar
  64. Melis M, Muntoni AL, Pistis M (2012) Endocannabinoids and the processing of value-related signals. Front Pharmacol 3:7PubMedCentralPubMedCrossRefGoogle Scholar
  65. Mendelson JH, Babor TF, Kuehnle JC, Rossi AM, Bernstein JG, Mello NK, Greenberg I (1976) Behavioral and biologic aspects of marijuana use. Ann N Y Acad Sci 282:186–210PubMedCrossRefGoogle Scholar
  66. Milner JD, Wurtman RJ (1986) Catecholamine synthesis: physiological coupling to precursor supply. Biochem Pharmacol 35:875–881PubMedCrossRefGoogle Scholar
  67. Mogenson GJ, Yang CR (1991) The contribution of basal forebrain to limbic-motor integration and the mediation of motivation to action. Adv Exp Med Biol 295:267–290PubMedCrossRefGoogle Scholar
  68. Moja EA, Lucini V, Benedetti F, Lucca A (1996) Decrease in plasma phenylalanine and tyrosine after phenylalanine–tyrosine free amino acid solutions in man. Life Sci 58:2389–2395PubMedCrossRefGoogle Scholar
  69. Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, Wingham G, Lewis S, Curran HV (2011) Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 42(2):391–400Google Scholar
  70. Musty RE, Kaback L (1995) Relationships between motivation and depression in chronic marijuana users. Life Sci 56:2151–2158PubMedCrossRefGoogle Scholar
  71. NIMH Genetics Initiative (1992) Manual for the FIGS. National Institute of Mental Health, Saint LouisGoogle Scholar
  72. Oldendorf WH (1973) Stereospecificity of blood–brain barrier permeability to amino acids. Am J Physiol 224:967–969PubMedGoogle Scholar
  73. Palmour RM, Ervin FR, Baker GB, Young SN (1998) An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. Psychopharmacol (Berl) 136:1–7CrossRefGoogle Scholar
  74. Paronis CA, Nikas SP, Shukla VG, Makriyannis A (2012) Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol 23:802–805PubMedCentralPubMedCrossRefGoogle Scholar
  75. Patlak CS, Blasberg RG (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 5:584–590CrossRefGoogle Scholar
  76. Paule MG, Allen RR, Bailey JR, Scallet AC, Ali SF, Brown RM, Slikker W Jr (1992) Chronic marijuana smoke exposure in the rhesus monkey. II: Effects on progressive ratio and conditioned position responding. J Pharmacol Exp Ther 260:210–222PubMedGoogle Scholar
  77. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1–PL6PubMedGoogle Scholar
  78. Phillips LJ, Yung AR, McGorry PD (2000) Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust NZ J Psychiatry 34(Suppl):S164–S169CrossRefGoogle Scholar
  79. Prochaska JO, DiClemente C (1982) Transtheoretical therapy: toward a more integrative model of change. Psychother Theory Res Pract 19:276–288CrossRefGoogle Scholar
  80. Reilly D, Didcott P, Swift W, Hall W (1998) Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 93:837–846PubMedCrossRefGoogle Scholar
  81. Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain J Neurol 128:1314–1322CrossRefGoogle Scholar
  82. Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, Osman S, Brooks DJ (1994) The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 44:1292–1297PubMedCrossRefGoogle Scholar
  83. Schneider JS, Unguez G, Yuwiler A, Berg SC, Markham CH (1988) Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain J Neurol 111(Pt 6):1265–1285CrossRefGoogle Scholar
  84. Shen M, Thayer SA (1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55:8–13PubMedGoogle Scholar
  85. Sim LJ, Hampson RE, Deadwyler SA, Childers SR (1996) Effects of chronic treatment with Delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16:8057–8066PubMedGoogle Scholar
  86. Stiglick A, Kalant H (1983) Behavioral effects of prolonged administration of Delta 9-tetrahydrocannabinol in the rat. Psychopharmacology 80:325–330PubMedCrossRefGoogle Scholar
  87. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM (2009) Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage 48:186–190PubMedCrossRefGoogle Scholar
  88. Studholme C, Hill DL, Hawkes DJ (1996) Automated 3-D registration of MR and CT images of the head. Med Image Anal 1:163–175PubMedCrossRefGoogle Scholar
  89. Tam SY, Roth RH (1997) Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? Biochem Pharmacol 53:441–453PubMedCrossRefGoogle Scholar
  90. Temple EC, Brown RF, Hine DW (2011) The ‘grass ceiling’: limitations in the literature hinder our understanding of cannabis use and its consequences. Addiction 106:238–244PubMedCrossRefGoogle Scholar
  91. Tennant FS, Groesbeck CJ (1972) Psychiatric effects of hashish. Arch Gen Psychiatry 27:133–136PubMedCrossRefGoogle Scholar
  92. Terry-McElrath YM, O'Malley PM, Johnston LD (2008) Saying no to marijuana: why American youth report quitting or abstaining. J Stud Alcohol Drugs 69:796–805PubMedCentralPubMedGoogle Scholar
  93. Turkheimer FE, Brett M, Visvikis D, Cunningham VJ (1999) Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab 19:1189–1208PubMedCrossRefGoogle Scholar
  94. United Nations Office on Drugs and Crime (2010) World drug report. United Nations, New YorkGoogle Scholar
  95. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S, Haney M, Abi-Dargham A (2012) Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry 71:677–683PubMedCentralPubMedCrossRefGoogle Scholar
  96. van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF (2010) Chronic effects of cannabis use on the human reward system: an fMRI study. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 20:153–163CrossRefGoogle Scholar
  97. Verdejo-Garcia A, Rivas-Perez C, Lopez-Torrecillas F, Perez-Garcia M (2006) Differential impact of severity of drug use on frontal behavioral symptoms. Addict Behav 31:1373–1382PubMedCrossRefGoogle Scholar
  98. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002) Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 161:331–339PubMedCrossRefGoogle Scholar
  99. Wrase J, Schlagenhauf F, Kienast T, Wüstenberg T, Bermpohl F, Kahnt T, Beck A, Ströhle A, Juckel G, Knutson B, Heinz A (2007) Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics. Neuroimage 35:787–794PubMedCrossRefGoogle Scholar
  100. Zijlstra F, Veltman DJ, Booij J, van den Brink W, Franken IH (2009) Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug Alcohol Depend 99:183–192PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Michael A. P. Bloomfield
    • 1
    • 2
  • Celia J. A. Morgan
    • 3
    • 4
  • Shitij Kapur
    • 2
  • H. Valerie Curran
    • 3
  • Oliver D. Howes
    • 1
    • 2
    Email author
  1. 1.Psychiatric Imaging Group, Mansfield Building, Medical Research Council Clinical Sciences Centre, Institute of Clinical Sciences, Hammersmith HospitalImperial College LondonLondonUK
  2. 2.Department of Psychosis Studies, Institute of PsychiatryKing’s College London (King’s Health Partners)LondonUK
  3. 3.Clinical Psychopharmacology Unit, Division of Psychology & Language SciencesUniversity College LondonLondonUK
  4. 4.Washington Singer Laboratories, Department of PsychologyUniversity of ExeterExeterUK

Personalised recommendations